ContraVir Pharmaceuticals (CTRV) Competitors

ContraVir Pharmaceuticals (NASDAQ:CTRV) and Histogen (NASDAQ:HSTO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Which has more volatility & risk, CTRV or HSTO?

ContraVir Pharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Histogen has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Which has stronger valuation and earnings, CTRV or HSTO?

ContraVir Pharmaceuticals has higher earnings, but lower revenue than Histogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ContraVir Pharmaceuticals	N/A	N/A	-$9.45M	N/A	N/A
Histogen	$19K	5.06	-$10.62M	-$2.81	-0.01

Is CTRV or HSTO more profitable?

Histogen's return on equity of 0.00% beat ContraVir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ContraVir Pharmaceuticals	N/A	-4,810.77%	-130.14%
Histogen	N/A	N/A	N/A

Does the media prefer CTRV or HSTO?

In the previous week, ContraVir Pharmaceuticals' average media sentiment score of 0.00 equaled Histogen'saverage media sentiment score.

Company	Overall Sentiment
ContraVir Pharmaceuticals	Neutral
Histogen	Neutral

Do institutionals and insiders have more ownership in CTRV or HSTO?

1.1% of ContraVir Pharmaceuticals shares are owned by institutional investors. 1.6% of ContraVir Pharmaceuticals shares are owned by insiders. Comparatively, 3.3% of Histogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Histogen beats ContraVir Pharmaceuticals on 5 of the 7 factors compared between the two stocks.